Terms ending in 2039
Every in-force patent on Anavex Life Sciences Corp.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,280,034 | SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,622,955 | SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,180,174 | A2-73 Crystalline Polymorph Compositions of Matter and Methods of Use Thereof In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,138,240 | Treatment of Cardiac Dysfunction In force · Medium confidence | Anavex Life Sciences Corp. | In force | Medium confidence | |
| US 11,498,908 | A2-73 Crystalline Polymorph Compositions of Matter and Methods of Use Thereof In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.